TAURINE and HCC PATIENTS

Not Applicable

Completed

• Conditions: Taurine in HCC
• Interventions: Diagnostic Test: taurine level

• Registration Number: NCT04193761
• Lead Sponsor: Ain Shams University

Brief Summary

Serum taurine level beside (AFP and AFU) are of great value in early diagnosis in HCC Egyptian patients and may have a rule in identifying end-stage liver disease (ESLD) patients candidate for LDLT.

Detailed Description

Taurine has been demonstrated to have a direct and indirect antioxidant effect and to display antineoplastic activity by preventing angiogenesis and enhancing tumor cell apoptosis. Also it was suggested that measurement of serum taurine level in hepatic patients beside fibroscan is of great value in the early diagnosis of any fibrotic and cancerous liver changes.Aim of the work was to correlate serum taurine level with the levels of the specific tumor markers (α- fetoprotein and α-L-fucosidase ) for early diagnosis of different stages of HCC in Egyptian patients.

This observational case-control study was conducted in the Tropical Medicine Department, Ahmed Maher Teaching Hospital. Eighty hepatic patients were assigned to three groups (Chronic hepatitis, Cirrhosis and HCC). Twenty healthy subjects were enrolled as a control group. Serum levels of AFP, AFU, and taurine beside complete biochemical analysis and liver biopsies from all selected patients were done. Patients who accepted to be a candidate for living donor liver transplant (LDLT) were referred to Ain Shams University Specialized Hospital (ASUSH) liver transplant unit.

Study Timeline

• Study Start: 2017-03-17
• Primary Completion: 2018-04-20
• Study Completion: 2018-10-25
• Status Verified: 2019-12
• Study First Submitted: 2019-12-07
• Study First Submitted QC: 2019-12-09
• Last Update Submitted: 2019-12-09
• Study First Posted: 2019-12-10
• Last Update Posted: 2019-12-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Chronic hepatitis
• Cirrhosis
• HCC patients

Read More

Exclusion Criteria

• Patient refusal
• Bleeding tendency
• Tense ascites
• Inability to obtain a liver biopsy

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Chronic hepatitis	taurine level	-
Control	taurine level	-
Cirrhosis	taurine level	-
Hepatocellular carcinoma	taurine level	-

Primary Outcome Measures

Name	Time	Method
Taurine level among patients groups	8 months

Trial Locations

Locations (1)

Hanaa El Gendy; 🇪🇬 Cairo, Ain Shams University Specialized Hospital, Egypt